Benzinga's Top Analyst Calls From April 6, 2018

These headlines first appeared on Benzinga Pro.

Cantor out defending NewLink Genetics Corp NLNK, says indoximod is differentiated vs epacadostat in response rates in more heavily pretreated patient population; thinks assuming failure of indoximod may be premature, but understands shares are likely pressured.
Buckingham Research maintains Buy rating and $15 target price on Gol Transportes Aéreos GOL, implying 20 percent upside. Says Gol's underlying fundamental outlook is “aided by a continued demand recovery in the context of a heavily restructured supply backdrop and commercial initiatives.”
KeyBanc upgrades Halyard Health, Inc. HYH to Overweight, says upcoming events could raise growth expectations and restructuring and M&A efforts could drive accelerated EPS growth.
Mizuho out positive on Nektar Therapeutics NKTR, says Incyte’s INCY epacadostat Phase 3 failure is a positive for the company, believes this news raises the possibility of a takeout by BMS in coming months.
Imperial Capital maintains Outperform rating on Halcón Resources Corp. HK, says co. is “ready to get active on its West Quito Draw position” following acquisition.